siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells

Cellular and Molecular Biology

Volumn 61, Issue 2, 2015, Pages 98-103

  Montazami, N ^a   Kheirandish, M ^b   Majidi, J ^a   Yousefi, M ^a   Yousefi, B ^a   Mohamadnejad, L ^a   Shanebandi, D ^a   Estiar, M A ^c   Khaze, V ^a   Mansoori, B ^a   Baghbani, E ^d   Baradaran, Behzad ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colon cancer; MDR1; Oxaliplatin; P gp; SW480 cells

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; SMALL INTERFERING RNA; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; PLATINUM COMPLEX;

APOPTOSIS; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; MTT ASSAY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUNEL ASSAY; WESTERN BLOTTING; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84962031569     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.14715/cmb/2015.61.2.18     Document Type: Article

References (26)

1. World Health Organization. Cancer Incidence in Five Continents. Lyon: The World Health Organization and The International Agency for Research on Cancer. 2002
2. Esteva, F.J., Valero, V., Pusztai, L., Boehnke-Michaud, L., Buzdar, A.U., Hortobagyi, G.N., Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001, 6(2): 133-46. doi: 10.1634/theoncologist.6-2-133
3. Hortobagyi, G.N., Treatment of breast cancer. N. Engl. J. Med. 1998, 339 (18): 974-84. doi: 10.1056/NEJM199810013391407
4. Tourniqand, C., Andre, T., Achille, E., FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Clin. Oncol., 2004, 22 (2): 229-237. doi: 10.1200/JCO.2004.05.113
5. Harris, A.L., Hochhauser, D., Mechanisms of Multidrug Resistance in Cancer Treatment. Acta. Oncologica. 1992, 31(2): 205-13. doi: 10.3109/02841869209088904
6. Kellen, J.A., The reversal of multidrug resistance: an update. Exp. Ther. Onco. 2003, 3 (1): 5-13. doi: 10.1046/j.1359-4117.2003.01067.x
7. Krishna, R., Mayer, L.D., Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing pharmacokinetics of anticancer drugs. Eur. J. Pharma. Sci. 2000, 11(4): 265-83. doi: 10.1016/S0928-0987(00)00114-7
8. Giaccone, G., Pinedo, H., Drug Resistance. The Oncologist. 1996, 1(1 & 2):82-87.
9. Liu, Z., Qiu, M., Tang, Q.L., Liu, M., Lang, N., Bi, F., Establishment and biologic characteristics of oxaliplatin-resistant human colon cancer cell lines. Chin. J. Cancer. 2010, 29 (7): 661-7.
10. Cao, D.R., Yu, S.Y.X., P.H., Deng, Y.M., Method for Preparing Protopanoxadiol and Protopanaxatriol by Using Synergistic Oxidation and Alkaline Bydrolysis of Oxide and Hyperoxide. 2005. CN 200510100735.
11. Sharom, F.J., ABC multidrug transporters: structure, function and role ichemoresistance. Pharmacogenomic. 2008, 9 (1):105-27. doi: 10.2217/14622416.9.1.105
12. Raoul, C., Abbas-Terki, T., Bensadoun, J.C., Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 2005, 11(4):423-8. doi: 10.1038/nm1207
13. Hill, J.A., Ichim, T.E., Kusznieruk, K.P., Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. Immunol. 2003, 171(2):691-6. doi: 10.4049/jimmunol.171.2.691
14. Perez, J., Bardin, C., Rigal, C., Anthony, B., Rousseau, R., Dutour, A., Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer. Res.. 2011, 31(9):2813-20.
15. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001, 411(6836):494-8. doi: 10.1038/35078107
16. Xia, Z., Zhang, L., Chen, Q., Royal, C., Yu, Z., Liu, Z., Adam, B.L., Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol. Med. Rep. 2009, 2 (4):579-84. doi: 10.3892/mmr_00000140
17. Xia, Z., Zhu, Z., Zhang, L., Specific reversal of MDR1/P-gpdependent multidrug resistance by RNA interference in colon cancer cells. Oncol. Rep. 2008, 20 (6):1433-9. doi: 10.3892/or_00000163
18. Lincke, C.R., Smit, J.J., van der, Velde-Koerts, T., Borst, P., Structure of the human MDR3 gene and physical mapping of the human MDR locus. Biol. Chem. 1991, 266 (8):5303-10.
19. Duan, Z., Brakora, K.A., Seiden, M.V., Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer. Ther. 2004, 3 (7):833-8.
20. Wu, H., Hait, W.N., Yang, J.M., Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer. Res. 2003, 63 (7):1515-9.
21. Nieth, C., Priebsch, A., Stege, A., Lage, H., Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS. Lett. 2003, 545 (2-3):144-50. doi: 10.1016/S0014-5793(03)00523-4
22. Peng, Z., Xiao, Z., Wang, Y., Liu, P., Cai, Y., Lu, S., Feng, W., Han, Z.C., Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells. Cancer. Gene. Ther. 2004, 11 (11):707-12. doi: 10.1038/sj.cgt.7700738
23. Dong, H., Yao, L., Bi, W., Wang, F., Song, W., Lv, Y., Combination of survivinsiRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells. J. Cancer. Res. Ther. 2014, 26(5): 310-314
24. Lu, Z.J., Mathews, D.H., Fundamental differences in the equilibrium considerations for siRNA and antisense oligodeoxynucleotide design. Nucleic. Acids. Res. 2008, 36 (11):3738-45. doi: 10.1093/nar/gkn266
25. Bohula, E.A., Salisbury, A.J., Sohail, M., Playford, M.P., Riedemann, J., Southern, E.M., Macaulay, V.M., The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. Biol. Chem. 2003, 278 (18):15991-7. doi: 10.1074/jbc.M300714200
26. Holm, P.S., Lage, H., Bergmann, S., Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer. Res. 2004, 64 (1):322-8. doi: 10.1158/0008-5472.CAN-0482-2